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Abstract 
Aims. We compared thromboembolic (TE) and bleeding risks in patients with atrial fibrillation 
(AF) according to the new ‘Evaluated Heartvalves, Rheumatic or Artificial’ (EHRA) valve 
classification.  
Methods Patients were divided into 3 categories: (i) EHRA type 1 corresponds to the previous 
‘valvular’ AF patients, with either rheumatic mitral valve stenosis or mechanical prosthetic heart 
valves; (ii) EHRA type 2 includes AF patients with other valvular heart disease (VHD) and valve 
bioprosthesis or repair; and (iii) ‘non-VHD controls’ i.e. all AF patients with neither VHD nor post-
surgical valve disease.  
Results Among 8962 AF patients seen between 2000 and 2010, 357 (4%) were  EHRA type 1, 
1,754 (20%) were EHRA type 2 and 6,851 (76%) non-VHD controls. EHRA type 2 patients were 
older and had a higher CHA2DS2-VASc and HAS-BLED scores than either type 1 and non-VHD 
patients. After a mean follow-up of 1,264±1,160 days, the occurrence of TE events was higher in 
EHRA type 2 than non-VHD patients (HR (95%CI): 1.30 1.09-1.54), p=0.003; also, p=0.31 for type 
1 vs 2, p=0.68 for type 1 vs non-VHD controls). The rate of major BARC bleeding events for AF 
patients was higher in either EHRA type 1 (HR (95%CI): 3.16(2.11-4.72), p<0.0001) or type 2 (HR 
(95%CI): 2.19(1.69-2.84), p<0.0001) compared to non-VHD controls. 
Conclusion The EHRA valve classification of AF patients with VHD appears useful in categorizing 
these patients, in terms of TE and bleeding risks.  This classification can be used in clinical practice 
for appropriate choices of oral anticoagulation therapy and follow-up. 
 
Key words: atrial fibrillation, ischemic stroke, valvular heart disease, valve prosthesis. 
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INTRODUCTION  
Atrial fibrillation (AF) confers a substantial risk of fatal and disabling stroke and randomized trials 
have conclusively demonstrated that oral anticoagulation (OAC) reduces the risk of stroke/systemic 
embolism and all-cause mortality [1]. Valvular heart disease (VHD) is frequently (approximately 
30%) and independently associated with incident AF [2].  Such AF patients have been traditionally 
been dichotomized as ‘non valvular’ AF or ‘valvular’ AF [1,3], but different definitions have been 
used in clinical practice, guidelines and research studies, leading to possible confusion [4,5]. 
The term of ‘valvular AF’ usually applies to patients with AF associated with moderate-
severe mitral stenosis of rheumatic origin or to mechanical prosthetic valve replacements. These 
patients have a high TE risk even in sinus rhythm, which is even higher in case of associated AF, 
such that these patients require chronic OAC with VKA irrespective of their CHA2DS2-VASc score 
[1,6,7]. In ‘non valvular’ AF, guidelines recommended OAC use (ie. a Vitamin K Antagonist 
(VKA) or a NOAC), provided that the CHA2DS2-VASc score is ≥1 in males and ≥2 in females 
[1,8].  Of note, there is an increased embolic risk in ‘non-valvular AF’ patients with VHDs other 
than  severe mitral stenosis or mechanical prosthetic valves, compared with those with no VHD [9]. 
For example, AF patients with valvular bioprosthesis have a higher TE risk than those with ‘non-
valvular’ AF and the CHA2DS2VASc score (derived from ‘non-valvular AF’) is useful for TE risk 
prediction [10].  
How best to treat such patients?  Despite the absence of robust data, non-VKA oral 
anticoagulants (NOACs) has been proposed in patients who have AF associated with an aortic 
bioprosthesis >3months after implantation [15,16].  Indeed, recent subgroup analyses of 
randomized trials on AF support the use of NOACs in AF patients with aortic stenosis, aortic 
regurgitation or mitral regurgitation [11–14].  
When asked about the ‘valvular/non valvular’ AF definition, physicians have important 
uncertainties in their answers given the lack of a clear and accepted definition [5,17]. Recently, the 
‘Evaluated Heartvalves, Rheumatic or Artificial’ (EHRA) classification has been proposed for AF 
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patients with VHD [7]. The latter are categorized as EHRA type 1 which correspond to the current 
‘valvular’ AF patients; or EHRA type 2 that includes other VHD AF patients and post-surgical 
valve disease including valve repair, bioprosthesis, TAVI and Mitraclip. The aim of the present 
study was to compare thromboembolic risk in AF patients according to their EHRA valve 
classification status and secondly, to evaluate whether this classification would be more clinically 
relevant than the previous ‘valvular/non valvular’ AF definitions.  
 
METHODS 
Study population 
We included all patients with a diagnosis of AF seen in the cardiology department in our institution 
between January 2000 and December 2010. Patients’ characteristics were obtained from the records 
of our institution’s computerized codification system for each patient [9,10]. Patients with post-
surgical AF only were not included in the study. Patients were divided into 3 categories according 
to the EHRA valve classification, as follows: (i) EHRA type 1 VHD corresponds to the current 
‘valvular’ AF patients which includes those with either rheumatic mitral valve stenosis or 
mechanical valvular prosthesis [1]; (ii) EHRA type 2 VHD includes other VHD AF patients, valve 
repair, bioprosthesis, TAVI and Mitraclip; and (iii) non-VHD controls correspond to all AF patients 
without any VHD nor valvular prosthesis or repair. The CHA2DS2-VASc score, which has been 
validated in ‘non valvular AF’, and HAS-BLED score were calculated for each patient. VKA 
therapy was the only form of OAC used during the study period.  
Data on death and events during follow-up until December 2010 were obtained by searching 
in the medical database from consultation and hospitalization reports. The Regional University 
Hospital Centre (CHRU) of Tours serves approximately 400,000 inhabitants, is the only public 
institution in an area of about 4,000 km² and includes a total of 4 hospitals covering all medical and 
surgical specialties. We defined major bleeding using the Bleeding Academic Research Consortium 
(BARC) definitions [18]. Major BARC bleeding was defined as bleeding with a reduction in the 
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hemoglobin level of at least 20 g per litre, or with transfusion of at least 1 unit of blood, or 
symptomatic bleeding in a critical area or organ (e.g., intracranial, intraspinal, intraocular, 
retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome) or 
bleeding that causes death [18].  
The study was approved by the institutional review board of the Pole Coeur Thorax 
Vaisseaux from the Trousseau University Hospital, on December 7, 2010 and registered as a 
clinical audit. Ethical review was therefore not required and patient consent was not sought. The 
study was conducted retrospectively, patients were not involved in its conduct, and there was no 
impact on their care. 
 
Statistical analysis 
Comparisons between groups were made using chi-square tests to compare categorical variables, 
and the Student t test or the non-parametric Kruskal Wallis test where appropriate for continuous 
variables. A proportional hazard model was used to identify independent characteristics associated 
with the occurrence of an event during follow-up. The proportional hazard assumption was checked 
by plotting the log-log Kaplan Meier curves. The results were expressed as hazard ratios (HR) and 
95% confidence intervals (CI). Harrell’s c-statistic with 95% CIs was calculated as a measure of 
model performance. The CHA2DS2-VASc score was analysed as a continuous variable and as a 
categorical variable (low CHA2DS2-VASc risk if 0 in males or 1 in females, moderate if 1 in males 
and 2 in females, and high if >1 in males and >2 in females).  The C statistics were compared using 
the DeLong test. A p value <0.05 was considered statistically significant. Statview 5.0 (Abacus, 
Berkeley CA, USA), Medcalc 15.2 (MedCalc Software, Mariakerke, Belgium) and JMP 
®
 9.0.1 
(SAS Institute, Cary, NC, USA) were used for statistical analysis. 
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RESULTS 
A total of 8,962 patients suffering from AF were included in this study (Supplemental figure 1). 
True ‘valvular’ AF patients corresponding to EHRA type 1 was present in 357 (4%), consisting of 
124 with mitral stenosis and 243 mechanical valve prosthesis. For the ‘non valvular’ AF patients, 
1,754 (20%) belonged to EHRA type 2 and 6,851 (76%) were non-VHD controls. The 
characteristics of these patients are shown in Table 1.  
Non-VHD control AF patients were younger, more frequently women and were more prone 
to have permanent AF than other patients.   EHRA type 2 patients were older and had more heart 
failure, coronary artery disease and previous myocardial infarction, hypertension, renal 
insufficiency, diabetes mellitus, and hyperlipidaemia than EHRA type 1 and non-VHD controls. 
Thus, the average CHA2DS2-VASc and HAS-BLED scores in EHRA type 2 patients were higher. 
Concerning medical therapies, type 1 AF patients more frequently received OAC (78%) and type 2 
were more commonly treated with angiotensin converting enzyme (ACE) or angiotensin 2-blocker 
(47%), beta-blockers (45%) and diuretics (62%). 
 
Thromboembolic events 
The mean follow-up period was 1,264±1,160 days (median 922 days, interquartile range 234-
2,083), and there were 715 TE events. The rate of TE events for AF patients was significantly 
higher (1.30 (95%CI: 1.09-1.54), p=0.003) in EHRA type 2 than non-VHD controls (p=0.012 for 
overall Log rank test; p=0.31 for type 1 vs 2, p=0.68 for type 1 vs non-VHD controls) (figure 1). 
After adjustment for age, gender and anticoagulant use, there was no significant differences 
between the 3 groups. Increasing age and CHA2DS2-VASc score were independently associated 
with an increased risk of TE events (Supplemental table 2). Oral anticoagulation and female gender 
were independently associated with a lower risk of TE events. Distinguishing patients according to 
the EHRA valve classification among type 2 and non-VHD controls was not an independent 
predictor of TE events after adjustment for confounding factors. 
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 Using c-statistics, we measured the performance of the CHA2DS2-VASc score in the VHD 
patients (Table 2). The CHA2DS2-VASc score as continuous variable significantly better predicted 
TE risk in non-VHD controls compared to EHRA type 2 patients in the non-anticoagulated sub-
group, with a similar finding in the overall AF population. Prediction was non-significantly 
different between EHRA type 1 and type 2 patients (except for non-anticoagulated patients when 
analysed as continuous variable) nor between type 1 and non-VHD controls.  
In supplemental table 1, a modelling analysis, based on metaanalysis by Ruff et al [19], 
would show the added advantage of NOACs in reducing event rates in moderate-high risk patients 
based on the CHA2DS2-VASc score. In addition, the CHA2DS2-VASc score performed similarly 
well in identifying ‘low risk’ patients whether the AF patients was EHRA type 2 or non-VHD 
controls. Increasing age and CHA2DS2-VASc score were independently associated with an 
increased risk of TE events (Supplemental table 2).  
  
Bleeding events 
The rate of major BARC bleeding events for AF patients was different according to the EHRA type 
(p<0.0001 for the overall Log rank test, p=0.10 for type 1 vs 2, p<0.0001 for type 1 vs non-VHD 
controls and p<0.0001 for type 2 vs non-VHD controls) (figure 1). After adjustment for age, gender, 
antiplatelet therapy (APT) and anticoagulant use, type 1 and type 2 patients respectively had a 2.73 
(95% CI: 1.72-4.31, p<0.0001) and 2.05 (95% CI: 1.55-2.70, p<0.0001) fold increased risk of major 
BARC bleeding than non-VHD patients. There was no difference between type 1 and 2 after 
adjustment for confounding factors.  
C-statistics for the HAS-BLED score showed better prediction of major BARC bleeding in 
non-VHD controls vs type 2, and type 2 vs type 1 in the overall population (table 3). In patients on 
VKA, the area under the curve (AUC) for non-VHD patients was significantly higher than the other 
patient groups. Supplemental table 3 shows major bleeding annual rates for each of the study 
groups.  
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DISCUSSION 
In this study, we have shown that dividing the AF population according to the new EHRA 
classification for valvular AF allows differentiation of different risk profiles. Specifically, EHRA 
type 2 patients, now corresponding to AF patients with VHD or valve repair, had a higher TE risk 
than non-VHD control patients (ie. ‘non valvular’ AF patient without any valve disease or surgery). 
Second, a higher CHA2DS2-VASc score was likely to explain the increased risk in these AF patients 
with VHD.   
 
In our cohort, 20% were EHRA type 2 AF patients, and these were generally pooled with 
non-VHD AF patients in the older definitions of the ‘non valvular’ AF group. Indeed, the higher TE 
risk of EHRA type 2 patients can be attributable to an older age and more frequent comorbidities, 
de facto increasing the CHA2DS2-VASc score. These observations have previously been reported 
with a significant difference for TE risk in VHD and only a trend for bioprosthesis [9,10]. EHRA 
Type 1 patients corresponding to ‘valvular’ AF had a non-significant TE risk when compared to 
type 2 and non-VHD controls, partly related to the higher rate of OAC use, reaching 78%.   
Increasing age and CHA2DS2-VASc score were the main variables that were independent 
predictors of TE events. Although the predictive value of the CHA2DS2-VASc score was lower in 
type 2 vs non-VHD controls in non-anticoagulated patients (and vs type 1) in contrast to previous 
studies [9,10], the score performed well in identifying ‘low risk’ patients in all groups. ‘Low risk’ 
patients had a low rate of TE events regardless of their AF type and OAC was not associated with 
any benefit in this setting. There was underuse of anticoagulation in the EHRA type 1 group, where 
all should ideally be on anticoagulation. This might be related to prior bleeding, severe 
comorbidities or paroxysmal AF of short duration in some patients.  
OAC is generally recommended when the yearly rate of TE events is expected to be above 
1% for patients with a so-called ‘non-valvular’ AF [1]. Our results suggest that no OAC might be 
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acceptable in these patients (EHRA type 2 and non-VHD patients) at low-risk of TE events, 
particularly when they have a high HAS-BLED score and/or when bleeding events are documented 
with OAC.  
 
 Major bleeding risk was significantly higher in type 1 and 2 vs non-VHD control patients, 
and the higher rate of anticoagulant prescription may in part explain this result. Once adjusted for 
antiplatelet therapy and VKA use, the risk of major bleeding events was still 2-fold higher in type 2 
vs non-VHD controls. Whether the differences in bleeding events are a play of chance, are a true 
biological effect, or reflect unidentified confounding effects (e.g. differences in practice patterns) 
remain uncertain. Patients with VHD more frequently had higher HAS-BLED score and/or OAC 
during the course of the study and this would be possible explanations even after adjustment. The 
higher incidence of major bleeding events in type 2 vs non-VHD control patients has already been 
observed in patients taking NOACs in subgroup analyses of randomized trials [11–13]. The 
presence of any VHD or post-surgical valve disease did not influence the comparison of NOAC 
with warfarin in these trials, with a lower risk of bleeding events also found in “real life” data [20], 
except for Rivaroxaban which was the only NOAC associated with a higher risk of bleeding than 
VKA in such patients [11].  Nevertheless, he use of NOACs is discouraged in patients who have AF 
associated with mitral stenosis and strictly contraindicated with any mechanical prostheses (with 
Grade IIIC and IIIB recommendations, respectively) given their particularly high thromboembolic 
risk [1,6].  Indeed, the negative experience with dabigatran etexilate has halted the investigation of 
other NOACs (eg. FXa inhibitors) in such patients [21].  
 
Limitations 
This study was based on a registry and is subject to the limitations inherent to retrospective 
observational analyses. The study population was hospital-based and therefore may not be 
representative of all patients with AF. The study was not ethnically diverse and our findings may 
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not be generalizable to other populations. Another caveat is that we did not have access to data on 
events occurring outside of our area. There were also numerous variables to be taken into account, 
and it is possible that we had overlooked confounding factors, which might affect the value of 
multivariable statistical analysis. Otherwise, as our study extends from 2000 to 2010, and patients 
were not yet taking NOACs. Without any such patients, we only made assumptive projections for 
NOACs whereas the others were based upon observation. Finally, we had access neither to precise 
variations in antithrombotic treatment during follow-up, nor to levels of anticoagulation by serial 
measurements of the INR, a common limitation in such ‘real life’ observational analysis. 
 
CONCLUSION 
The EHRA valve classification of AF patients with VHD appears useful in categorizing these 
patients, in terms of TE and bleeding risks.  This classification can be used in clinical practice for 
appropriate choices of OAC therapy and follow-up.  
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Figure legends 
 
 
Figure 1. Top panel: Stroke and/or thromboembolic events in patients with atrial fibrillation 
according to the EHRA valve classification status. Lower panel: Major BARC bleeding events in 
patients with atrial fibrillation according to the EHRA valve classification status. 
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Table 1. Characteristics of the patients with AF according to EHRA valve classification  
 
 
Variable 
EHRA 
Type 1 
n= 357(4%) 
EHRA 
Type 2 
n= 1,754(20%) 
EHRA 
Non-VHD 
 n= 6,851(76%) 
p 
Age (years) (meanSD)  6813 7511 7015 <0.0001 
Women  198(55%) 704(40%) 2,565(37%) <0.0001 
Heart failure 243(68%) 1,281(73%) 3,388(49%) <0.0001 
Coronary artery disease  86(24%) 609(35%) 2,023(30%) <0.0001 
Previous myocardial infarction  24(7%) 295(17%) 979(14%) <0.0001 
Pacemaker or implantable cardioverter 
defibrillator  
77(22%) 325(19%) 1,130(16%) 0.009 
Hypertension  97(27%) 785(45%) 2,861(42%) <0.0001 
Previous ischaemic stroke  32(9%) 142(8%) 564(8%) 0.86 
Renal insufficiency  46(13%) 240(14%) 522(8%) <0.0001 
Diabetes mellitus  51(14%) 300(17%) 1,058(15%) 0.18 
Chronic obstructive pulmonary disease  42(12%) 206(12%) 703(10%) 0.15 
Hyperlipidaemia 65(18%) 395(23%) 1,304(19%) 0.004 
Permanent atrial fibrillation  205(57%) 850(48%) 2,440(36%) <0.0001 
CHA2DS2VASc score (meanSD) 31.7 3.61.6 2.91.8 <0.0001 
HASBLED score (meanSD)  1.41.1 1.91.1 1.51.1 <0.0001 
Left ventricular ejection fraction 
(meanSD) (n=1,934) 
5317 4816 4616 <0.0001 
Left ventricular ejection fraction <45 % 
(n=1,934) 
36(31%) 298(46%) 552(47%) 0.005 
Medication during follow-up     
Oral anticoagulation (n=8,120) 258(78%) 971(61%) 3,408(55%) <0.0001 
Antiplatelet therapy (n=7,969) 56(17%) 529(34%) 2,095(34%) <0.0001 
Angiotensin converting enzyme inhibitor 
or Angiotensin 2-blocker (n=8,671) 
134(38%) 809(47%) 2,106(32%) <0.0001 
Beta-blocker (n=8,767) 152(44%) 778(45%) 2,976(44%) 0.84 
Diuretic (n=8,224) 
Digoxine (n=8,871) 
203(60%) 
149(42%) 
1,033(62%) 
570(33%) 
2,122(34%) 
1,440(21%) 
<0.0001 
<0.0001 
Class III antiarrhythmic agent (n=8,862) 156(44%) 783(45%) 2,754(41%) 0.003 
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Table 2. Comparison of c-statistics (95% confidence intervals) for CHA2DS2VASc scoring system according to EHRA valve classification type 
patients with atrial fibrillation 
 
a 
C-statistic calculated as area-under-the-curve for the receiver-operator characteristic (ROC) 
b 
p<0.05 vs type 1 
c 
NS vs type 1 
 C statistic (95% CI)
a 
 EHRA Type 1 EHRA Type 2 EHRA Non-VHD p value 
Type 2 vs Non-VHD 
CHA2DS2VASc as a continuous variable 
All patients (n=329) 
0.657(0.606-0.708) 
(n=1,598) 
0.629(0.605-0.653)
c 
(n=6,193) 
0.655(0.643-0.667)
c 
0.05 
Patients not on VKA (n=71) 
0.729(0.616-0.819) 
(n=627) 
0.577(0.538-0.615)
b
 
(n=2,785) 
0.666(0.648-0.683)
c 
<0.0001 
Patients on VKA (n=258) 
0.630(0.570-0.687) 
(n=971) 
0.661(0.630-0.690)
c 
(n=3,408) 
0.646(0.630-662)
c 
0.39 
CHA2DS2VASc as a categorical variable (low, moderate or high risk) 
All patients (n=329) 
0.591(0.538-0.644) 
(n=1,598) 
0.534(0.510-0.558)
c 
(n=6,193) 
0.601(0.589-0.613)
c 
<0.0001 
Patients not on VKA (n=71) 
0.595(0.479-0.701) 
(n=627) 
0.512(0.473-0.551)
c 
(n=2,785) 
0.624(0.606-0.642)
c 
<0.0001 
Patients on VKA (n=258) 
0.587(0.526-0.645) 
(n=971) 
0.547(0.516-0.578)
c 
(n=3,408) 
0.582(0.565-0.599)
c
 
0.0524 
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Table 3. Comparison of c-statistics (95% confidence intervals) for identifying the risk of major BARC bleeding events using the HASBLED scoring 
system according to EHRA valve classification type patients with atrial fibrillation. 
 
 
 
a 
C-statistic calculated as area-under-the-curve for the receiver-operator characteristic (ROC) 
b 
p<0.05 vs type 1 
c 
NS vs type 1 or incalculable 
 C statistic (95% CI)
a 
 EHRA 
Type 1 
EHRA 
Type 2 
EHRA 
Non-VHD 
p value 
type 2 vs Non-VHD 
HASBLED as a continuous variable 
All patients (n=329) 
0.505(0.451-0.559) 
(n=1,598) 
0.574(0.550-0.598)
b 
(n=6,193) 
0.645(0.633-0.657)
b 
<0.0001 
Patients not on VKA (n=71) 
0.641(0.529-0.753) 
(n=627) 
0.600(0.562-0.638)
c
 
(n=2,785) 
0.640(0.622-0.658)
c 
0.06 
Patients on VKA (n=258) 
0.545(0.484-0.606) 
(n=971) 
0.577(0.546-0.608)
c 
(n=3,408) 
0.649(0.633-0.665)
b 
0.0001 
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Highlights 
 
 A new definition of ‘valvular/non-valvular’ atrial fibrillation has been proposed.  
 This new EHRA valve classification is clearer than the previous ones. 
 It results in homogenous groups of patients for thromboembolic and bleeding risks.  
 This classification should be useful in research for harmonization of studies. 
 It may help daily practice for appropriate choices of anticoagulant and follow-up.  
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